Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-κB activity

@article{Yang2005FenofibrateDA,
  title={Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-$\kappa$B activity},
  author={Tian-lun Yang and Meifang Chen and Bai-Lin Luo and Qi-ying Xie and Jun-Lin Jiang and Yuan‐jian Li},
  journal={Naunyn-Schmiedeberg's Archives of Pharmacology},
  year={2005},
  volume={371},
  pages={401-407}
}
Previous investigations have demonstrated that endogenous inhibitors of nitric oxide synthase (NOS), such as asymmetric dimethylarginine (ADMA), contribute importantly to endothelial dysfunction, and that fenofibrate has a protective effect on the endothelium in rats treated with low-density lipoprotein (LDL) by reducing ADMA levels. In the present study, we explored further the possible mechanism underlying inhibition of ADMA generation by fenofibrate in cultured human umbilical vein… 
Role of Asymmetric Dimethylarginine in Inflammatory Reactions by Angiotensin II
TLDR
ADMA is a potential proinflammatory factor and may be involved in the inflammatory reaction induced by Ang II, and is suggested to be a novel inflammatory factor.
Vaspin Increases Nitric Oxide Bioavailability through the Reduction of Asymmetric Dimethylarginine in Vascular Endothelial Cells
TLDR
Results suggest that vaspin increases eNOS activity by reducing ADMA level through STAT3-mediated regulation of DDAH II expression, which provides a novel molecular mechanism of antiatherogenic actions of vaspIn conclusion, this study suggests that vospin protects against atherosclerosis through its beneficial effects on the ADMA-eNOS system.
Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems.
TLDR
Evidence of rapidly evolving evidence of isoform-specific distribution and regulation of DDAH expression in the kidney and blood vessels provides potential mechanisms for nephron site-specific regulation of NO production.
The Protective Effect of Fenofibrate Against TNF-α-Induced CD40 Expression through SIRT1-Mediated Deacetylation of NF-κB in Endothelial Cells
TLDR
The results indicate that fenofibrate has protective effect against TNF-α-induced CD40 expression through SIRT1-mediated deacetylation of the p65 subunit of NF-κB.
Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease
TLDR
The current role of ADMA and D DAH in vascular health and disease, the techniques used to assess DDAH activity and expression, and the results of recent studies on pharmacological and biological agents modulating DDAh activity andexpression are discussed.
Pyrrolidine dithiocarbamate ameliorates endothelial dysfunction in thoracic aorta of diabetic rats by preserving vascular DDAH activity
TLDR
Results indicate that PDTC could ameliorate impairment of endothelium-dependent relaxation in diabetic rats and provides a new strategy for treatment of diabetic cardiovascular complications.
Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia
TLDR
Results suggest that the beneficial effect of fenofibrate on the endothelium in hypertriglyceridemic individuals may be related to reduction of ADMA level.
Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches.
TLDR
Novel therapeutic approaches targeting selectively ADMA are encouraging, but have only been tested in vitro or in animal studies and further research is needed in order to conclude on how therapeutic strategies modulating ADMA actions can affect atherosclerosis progression and cardiovascular diseases.
Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy.
TLDR
The increased concentration of ADMA is positively correlated with markers of atherosclerosis, such as carotid artery intima-media thickness and has a predictive value for acute cardiovascular events in prospective studies.
...
...

References

SHOWING 1-10 OF 43 REFERENCES
Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase.
TLDR
The results suggest that the endothelial vasodilator dysfunction observed in hypercholesterolemia may be due to reduced degradation of ADMA, the endogenous inhibitor of NOS.
Effect of simvastatin on endothelium-dependent vaso-relaxation and endogenous nitric oxide synthase inhibitor.
TLDR
SimVastatin protect the vascular endothelium against the damages induced by LDL or ox-LDL in rats or cultured ECV304 cells, and the beneficial effects of simvastatin may be related to the reduction of inflammatory cytokine TNF-alpha level.
Effect of fenofibrate on LDL-induced endothelial dysfunction in rats
TLDR
The results suggest that the protective effect of fenofibrate on endothelial cells in rats treated with LDL may be related to the reduction of ADMA concentration.
Protective effects of daviditin A against endothelial damage induced by lysophosphatidylcholine
TLDR
The present results suggest that daviditin A preserves endothelial dysfunction elicited by LPC, and the protective effect of davidit in A on the endothelium is related to reduction of ADMA concentration.
Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level
TLDR
The results suggest that a single injection of native LDL causes endothelial dysfunction by elevation of ADMA levels and that the protective effect of probucol on endothelial cells is related to reduction ofADMA concentration.
The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
Endogenous inhibitors of nitric oxide synthesis and lipid peroxidation in hyperlipidemic rabbits.
TLDR
An increase in serum concentration of DMA may be secondary to the elevation of lipid peroxides in the hyperlipidemic rabbit, and supplementation with vitamin E decreased MDA and DMA content and improved the endothelium-dependent vasodilation.
Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study.
  • R. SaranJames E. Novak S. Rajagopalan
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2003
TLDR
Antioxidant therapy with vitamin E has the potential to lower ADMA levels in CKD patients, implying increased NO.
Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis.
TLDR
The results suggest that this endogenous antagonist of NO synthase may be a marker of atherosclerosis.
...
...